Sentence examples for mutations in triple from inspiring English sources

Exon 9 and 20 PIK3CA mutations in triple negative breast cancer specimens.

The high frequency of TP53 mutations in triple negative breast cancer (TNBC: negative for estrogen receptor, progesterone receptor, and HER2) make Chk1 an attractive therapeutic target.

Churpek et al. [ 40] reported a pick-up rate of 26%% (47/180) for pathogenic mutations in a group of black patients with early onset disease (age of diagnosis <45) and 25%% pick-up rate (26/103) for pathogenic mutations in triple negative black patients.

We also observed a low frequency (12.5%) of PIK3CA mutations in triple-negative tumors (ER-/PR-/ERBB2), a subgroup reported to overlap with the basal-like subtype of breast cancer.

Numerous studies have investigated the rate of BRCA1/2 mutations in triple-negative breast cancer (TNBC), with reported mutation rates ranging from 10 to 40% in this breast cancer subtype [ 3- 8].

We read with interest the study by Teng and colleagues reporting a high frequency (11.4 %) of epidermal growth factor receptor (EGFR -activating mutations in triplEGFR -activatingt cancer (TNBC) in a Singapore cohort [ 1].

EGFR-TKIs were offered in the second or further lines of treatment in patients with KRAS mutations or in triple negative according to clinical practice (Kim et al, 2008; Shepherd et al, 2009; Cappuzzo et al, 2010).

These results suggest that the L642Q mutation compromises the binding of NEDD1 to γ-tubulin in vivo, and that the additional mutations in the triple L642Q/L649Q/L656Q mutant have an additive effect, although the individual mutants did not disrupt binding (Figure 5A).

The mutations in the triple mutant were TTCCATG CC (for 3 n), TTCGTTTG TT (for 5′ 4 n) and TTCAGGGG TT (for 3′ 4 n).

In contrast, proteins with normal NC1 domains and with missense mutations in the triple-helix-forming domain are expected to be incorporated into heterotrimers during their assembly.

Therefore, we found no evidence of KRAS somatic mutations in human triple-negative tumors as measured by a standarized assay [ 44, 45].